Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00836147 · ClinicalTrials.gov registry record · Phase 1
Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids
A Phase 1 study, sponsored by Renovo.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00836147 is a Phase 1 study that has completed, run by Renovo. The registered enrollment target is 20 participants.
The verdict
NCT00836147, a Phase 1 study, has completed, sponsored by Renovo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This trial will explore the efficacy and safety of 250ng Juvista per Linear cm, administered by intradermal injection following the excision of ear lobe keloids. Keloids commonly occur after ear piercing and are usually bilateral.One ear lobe will be treated with Juvist and one with placebo.
Interventions
- DRUG Placebo
- DRUG Avotermin (Juvista)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00836147
The ClinicalTrials.gov registry entry for NCT00836147 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Renovo, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00836147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00836147 about?
NCT00836147 is a clinical study titled "Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids". This trial will explore the efficacy and safety of 250ng Juvista per Linear cm, administered by intradermal injection following the excision of ear lobe keloids. Keloids commonly occur after ear piercing and are usually bilateral.One ear lobe will be treated with Juvist and one with placebo.
What is the current status of trial NCT00836147?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-02. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00836147?
The interventions under investigation include: Placebo (DRUG), Avotermin (Juvista) (DRUG).
Who is sponsoring clinical trial NCT00836147?
This trial is sponsored by Renovo, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.